Clinical trial
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary…
NCT00332852 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00332852 |
|---|---|
| Title | Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer |
| Official title | An Open Phase III Trial With Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 655 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2010 |
| First posted | Jun 2, 2006 |
| Last update posted | Feb 23, 2017 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: